PKM and lung carcinoma: However, lncRNA H19 has been found to be downregulated in erlotinib‐resistant EGFR mutant lung cancer cells and can regulate resistance to erlotinib by interaction with pyruvate kinase M2 (PKM2) and activation of a Src‐dependent Akt signaling pathway (Figure 7).172, 173